MAIA Biotechnology, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Financial statements are unaudited. MAIA is a clinical-stage oncology biotechnology company; it had no revenue and is developing THIO, including for non-small cell lung cancer.
Financial position and results
- Q2 2022: Operating expenses were $3.44 million, including $2.12 million of research and development (R&D) and $1.32 million of general and administrative (G&A) expenses. Net loss attributable to MAIA shareholders was $3.31 million, or $0.40 per share, compared with $3.43 million, or $0.78 per share, in Q2 2021. Weighted-average shares rose to 8.20 million from 4.37 million.
- First half 2022: Operating expenses were $6.89 million (R&D $4.20 million; G&A $2.69 million). Net loss was $6.72 million; net loss attributable to MAIA shareholders was $7.17 million, or $0.90 per share, versus $4.41 million, or $1.01 per share, in first half 2021. The 2022 attributable loss includes a $450,578 deemed dividend from a warrant modification.
- Period comparison: Q2 operating expenses increased 129% year over year; first-half expenses increased 170%. R&D growth chiefly reflected THIO-101 clinical preparation and startup and increased staffing. G&A growth reflected payroll, professional fees, and other costs. Q2 net loss was lower than the prior year’s despite higher operating costs, primarily because 2021 included warrant and embedded-feature fair-value expenses and convertible-note interest.
- Cash flow: First-half operating cash use was $4.83 million, versus $1.20 million in 2021. Financing provided $2.41 million, compared with $7.32 million in 2021. Cash decreased $2.42 million during the half to $8.15 million.
- Liquidity and debt: At June 30, cash was $8.15 million, current assets $8.61 million, current liabilities $3.10 million, and working capital $5.51 million. The balance sheet reported no debt. No revenue or meaningful operating margin was reported.
Funding, outlook, and material developments
- After quarter-end, MAIA completed its IPO and overallotment, selling 2.3 million shares at $5 per share. Net proceeds were approximately $9.2 million. The filing’s pro forma presentation shows cash of $17.32 million at June 30, 2022, adjusted for the offering and related share issuance.
- Management said available cash and subsequent financing proceeds were expected to fund operations through at least the next 12 months from issuance of the financial statements. MD&A separately says funds were sufficient for the next 24 months; the filing does not reconcile these runway estimates. MAIA expects continuing losses and will need additional capital to advance development.
- THIO-101 received Australian ethics approval; the first patient was dosed in Australia in July 2022. The company selected clinical sites in Australia and Europe and submitted an application for the European study. The FDA granted THIO orphan drug designation for hepatocellular carcinoma and small cell lung cancer.
- MAIA reported no material legal proceedings. It disclosed potential clinical, regulatory, funding, third-party manufacturing, key-personnel, and intellectual-property risks. COVID-19 and Russia’s invasion of Ukraine could affect operations; the company terminated planned research activities in Russia. It had not experienced COVID-related delays or increased costs at the time of filing but could in future.
- A Regeneron agreement supplies cemiplimab for a planned NSCLC trial at no charge, but grants Regeneron development exclusivity in NSCLC during the trial, expected to last two years. UTSW license agreements include milestone payments, capped at a combined $112 million per agreement, and royalties; no milestones were due as of June 30, 2022.
- Disclosure controls were found ineffective due to a material weakness in financial-information review and approval controls and lack of segregation of duties. Management said it was taking remediation steps, including hiring accounting staff.
Important facts for investors to verify
- Clarify the difference between management’s stated 12-month and 24-month cash runway estimates and assess the expected cash needs of THIO-101 and other programs.
- Track THIO-101 enrollment, safety and efficacy updates, European trial authorization, and any effects of trial execution or external disruptions.
- Monitor operating cash burn, R&D and G&A growth, and the timing and terms of any future financing and resulting dilution.
- Review progress in remediating the material weakness and whether disclosure controls become effective.
- Assess the terms and potential financial exposure of the UTSW licenses and the NSCLC exclusivity arrangement with Regeneron.